Answers are grounded in this paper and cite their sources.
Multiple myeloma (MM) is a plasma cell (PC) malignancy that typically affects elderly patients. The outcome in terms of overall survival (OS) is heterogeneous, depending on the biology of the disease itself, prognostic factors and responses to therapy. 1 The treatment landscape for MM has improved greatly, 2 leading to deeper remissions and prolonged progression-free survival (PFS) and OS. 3 These advances created the need for highly sen-sitive means to detect minimal residual disease (MRD), which is valuable for the evaluation of depth of responses and therapy monitoring. The aim now is to use MRD as a surrogate endpoint, rather than later endpoints (i.e., PFS and/or OS) which need long periods of time to mature, until they may show meaningful differences resulting from the allocation of novel therapies. 5 Multiparameter flow cytometry (MFC) enables detection of residual aberrant PC (aPC) with high sensitivity. 6 Currently, there are several MFC options available, including EuroFlow and other analyses. EuroFlow uses a two-tube, eight-color assay that ensures the currently aimed sensitivity of 10 -5 : the sample must be divided into two tubes and the haematologica 2020; 105:e523 MM: multiple myeloma; ID: initial diagnosis; PD: progressive disease; post-CTx: after standard chemotherapy; post-ASCT: after autologous stem cell transplantation; post-alloSCT: after allogeneic stem cell transplantation; SMM: smoldering multiple myeloma; MGUS: monoclonal gammopathy of undetermined significance. a Some patients were assessed more than once during the period of sampling. Every patient was only counted once for each cohort. The number of both cohorts together is higher than that of the entire cohort because some patients were assessed sequentially.
No takes yet. Share an insight, caveat, or question.
Dold et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: